89 related articles for article (PubMed ID: 19927364)
1. Different inflammatory responses induced by three LDL-lowering apheresis columns.
Hovland A; Hardersen R; Sexton J; Mollnes TE; Lappegård KT
J Clin Apher; 2009; 24(6):247-53. PubMed ID: 19927364
[TBL] [Abstract][Full Text] [Related]
2. Hematologic and hemostatic changes induced by different columns during LDL apheresis.
Hovland A; Hardersen R; Nielsen EW; Mollnes TE; Lappegård KT
J Clin Apher; 2010; 25(5):294-300. PubMed ID: 20806414
[TBL] [Abstract][Full Text] [Related]
3. LDL apheresis and inflammation--implications for atherosclerosis.
Hovland A; Lappegård KT; Mollnes TE
Scand J Immunol; 2012 Sep; 76(3):229-36. PubMed ID: 22670805
[TBL] [Abstract][Full Text] [Related]
4. Complement profile and activation mechanisms by different LDL apheresis systems.
Hovland A; Hardersen R; Nielsen EW; Enebakk T; Christiansen D; Ludviksen JK; Mollnes TE; Lappegård KT
Acta Biomater; 2012 Jul; 8(6):2288-96. PubMed ID: 22373816
[TBL] [Abstract][Full Text] [Related]
5. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
7. LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.
Lappegård KT; Enebakk T; Thunhaug H; Ludviksen JK; Mollnes TE; Hovland A
J Clin Lipidol; 2016; 10(6):1481-1487. PubMed ID: 27919366
[TBL] [Abstract][Full Text] [Related]
8. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
9. Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis.
Stefanutti C; Vivenzio A; Di Giacomo S; Ferraro PM
Cytokine; 2011 Aug; 55(2):245-50. PubMed ID: 21561790
[TBL] [Abstract][Full Text] [Related]
10. [Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis].
Bláha V; Zadák Z; Bláha M; Havel E; Solichová D; Brátová M; Malý J; Kmonícek L
Cas Lek Cesk; 1998 Jul; 137(14):424-9. PubMed ID: 9748737
[TBL] [Abstract][Full Text] [Related]
11. [Effects of LDL-apheresis--more than reduction of cholesterol?].
Schettler V; Wieland E
Dtsch Med Wochenschr; 2007 Mar; 132(11):575-8. PubMed ID: 17342636
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.
Palcoux JB; Atassi-Dumont M; Lefevre P; Hequet O; Schlienger JL; Brignon P; Roussel B
Ther Apher Dial; 2008 Jun; 12(3):195-201. PubMed ID: 18503695
[TBL] [Abstract][Full Text] [Related]
13. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Schneidewind JM; Latza R
ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
[TBL] [Abstract][Full Text] [Related]
14. Direct adsorption of lipoproteins from whole blood by direct adsorption of lipoprotein apheresis: first experience in two hypercholesterolemic children.
Bayrakci US; Besbas N; Ozcebe O; Coskun T; Akgul E; Kutluk T; Bakkaloglu A
Ther Apher Dial; 2005 Dec; 9(6):469-72. PubMed ID: 16354278
[TBL] [Abstract][Full Text] [Related]
15. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods].
Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M
Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708
[TBL] [Abstract][Full Text] [Related]
16. [LDL oxidation in homozygous familial hypercholesterolemia: effects of selective LDL-apheresis treatment].
Napoli C; Postiglione A; Scarpato N; Corso G; Ambrosio G; Condorelli M; Mancini M; Chiariello M
Cardiologia; 1996 May; 41(5):435-9. PubMed ID: 8767632
[TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells.
Cattin L; Petrucco A; Cazzolato G; Bon GB; Borelli V; Nardon E; Zabucchi G; Fonda M; Bordin P
ASAIO J; 1997; 43(3):209-13. PubMed ID: 9152493
[TBL] [Abstract][Full Text] [Related]
18. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different LDL apheresis methods.
Julius U; Frind A; Tselmin S; Kopprasch S; Poberschin I; Siegert G
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):629-39. PubMed ID: 18510481
[TBL] [Abstract][Full Text] [Related]
20. Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis.
Mol MJ; Stalenhoef AF
Neth J Med; 1990 Jun; 36(5-6):279-87. PubMed ID: 2395495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
